FCGR3A and autoimmune disease: This has been shown for example, for rituximab versus obinutuzumab.12 In autoimmune diseases, where autoantibody titres occur, such discriminatory capacity can be of the particular importance:29 On the other hand, higher affinity autoantibodies might be able to trigger CD16-CAR T cells on their own right and this consideration might call for autoimmunity as an exclusion criteria for the use of CD16-CAR T cells.